Gene therapy for spinal muscular atrophy
Recombinant adeno-associated virus vectors with codon-optimized SMN1 sequences and native promoters, combined with miR-122 binding sites, address toxicity issues in SMA treatment, enhancing safety and efficacy by minimizing liver and dorsal root ganglion toxicity, improving survival and muscle function.
Patent Information
- Application Number
- JP2024531048
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-05-13
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for spinal muscular atrophy (SMA), such as Zolgensma and nusinersen, face challenges with high toxicity, particularly liver toxicity and dorsal root ganglion toxicity, due to overexpression of SMN1 protein, which can lead to severe complications and reduced efficacy.
Development of recombinant adeno-associated virus (rAAV) vectors with codon-optimized SMN1 sequences and native SMN1 promoters, incorporating miR-122 binding sites to reduce liver toxicity and enhance targeted expression in the central nervous system, thereby minimizing off-target effects.
The rAAV vectors achieve safer and more effective SMN1 protein expression, reducing toxicity by 2-100-fold and improving survival and muscle function in SMA models, with enhanced therapeutic outcomes and reduced complications.
Smart Images

Figure 2024543132000001_ABST
Abstract
Description
[Technical field]
[0001] Related Applications This application claims the benefit under 35 U.S.C. § 119(e) of the filing date of U.S. Provisional Application No. 63 / 341,650, entitled "Gene Therapy for Spinal Muscular Atrophy," filed May 13, 2022, and U.S. Provisional Application No. 63 / 282,246, entitled "Gene Therapy for Spinal Muscular Atrophy," filed November 23, 2021; the contents of each are incorporated herein by reference in their entirety.
[0002] Electronic Sequence Listing Reference The contents of the electronic sequence listing (U012070171WO00-SEQ-LJG.xml; size: 48,435 bytes; and creation date: November 18, 2022) are incorporated herein by reference in their entirety. [Background technology]
[0003] background Spinal muscular atrophy (SMA) is a neuromuscular disease caused by loss of survival function of motor neuron 1 (SMN1) gene and is characterized by degeneration of motor neurons and progressive muscle weakness. SMA affects approximately 1 in 11,000 newborns and remains the leading genetic cause of infant death. In the past decade, two major advances to treat this devastating disease have been achieved by increasing SMN protein in human patients. The first is the antisense oligonucleotides (ASOs), nusinersen and risdiplam, which modify the splicing of existing SMN2 pre-mRNA. The second is Zolgensma, a self-complementary adeno-associated virus 9 (scAAV9)-mediated SMN1 gene replacement. DISCLOSURE OF THEINVENTION
[0004] overview Aspects of the present disclosure relate to compositions and methods for treating spinal muscular atrophy (SMA). The present disclosure is based in part on isolated nucleic acids and vectors (e.g., viral vectors, such as rAAV vectors) encoding SMN1. In some embodiments, SMN1 expression is driven by the native SMN1 promoter or a variant thereof. In some embodiments, the isolated nucleic acids and vectors of the present disclosure have reduced toxicity and / or increased transgene expression compared to previously described vectors encoding SMN.
[0005] Thus, in some aspects, the disclosure provides a recombinant adeno-associated virus (rAAV) vector comprising a transgene comprising an endogenous SMN1 promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs). In some embodiments, the codon-optimized nucleic acid sequence comprises a nucleic acid sequence at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:1. In some embodiments, the codon-optimized nucleic acid sequence comprises or consists of the sequence represented by SEQ ID NO:1. In some embodiments, the codon-optimized nucleic acid sequence does not comprise the nucleic acid sequence represented by SEQ ID NO:2. In some embodiments, the human SMN1 comprises the amino acid sequence represented by SEQ ID NO:3.
[0006] In some embodiments, the endogenous SMN1 promoter is a human SMN1 promoter. In some embodiments, the endogenous SMN1 promoter comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:4 or 5. In some embodiments, the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:4. In some embodiments, the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:5.
[0007] In some embodiments, the recombinant adeno-associated virus (rAAV) vector comprises a promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and a transgene flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the promoter is a constitutive promoter.In some embodiments, the promoter is a CB6 promoter.In some embodiments, the rAAV vector further comprises a CMV enhancer.
[0008] In some embodiments, the rAAV vector further comprises one or more miR-122 binding sites. In some embodiments, the one or more miR-122 binding sites are located between the codon-optimized nucleic acid sequence encoding human SMN1 and the 3' ITR. In some embodiments, the rAAV vector comprises a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NOs:9-11.
[0009] In some embodiments, at least one AAV ITR is an AAV2 ITR. In some embodiments, at least one AAV ITR is a mutated ITR (mTR). In some aspects, the present disclosure provides a vector comprising the rAAV vector described herein. In some embodiments, the vector is a plasmid or a baculovirus vector. In some aspects, the present disclosure provides a cell comprising the rAAV vector described herein or the vector described herein.In some embodiments, the cell is a prokaryotic cell or a eukaryotic cell.In some embodiments, the cell is a mammalian cell, a bacterial cell, or an insect cell (for example, SF9 cell).
[0010] In some aspects, the disclosure provides an isolated nucleic acid comprising a nucleic acid sequence represented by any one of SEQ ID NO:1, SEQ ID NO:6, or SEQ ID NO:7. In some embodiments, the isolated nucleic acid further comprises an endogenous SMN1 promoter operably linked to the nucleic acid sequence. In some embodiments, the endogenous SMN1 promoter is a human SMN1 promoter. In some embodiments, the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO: 4 or 5.
[0011] In some aspects, the disclosure provides a recombinant adeno-associated virus (rAAV) comprising: a recombinant adeno-associated virus (rAAV) vector comprising a transgene comprising an endogenous SMN1 promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and flanked by AAV inverted terminal repeats (ITRs); and at least one AAV capsid protein.
[0012] In some embodiments, the codon-optimized nucleic acid sequence comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO: 1. In some embodiments, the codon-optimized nucleic acid sequence comprises or consists of the sequence represented by SEQ ID NO: 1. In some embodiments, the codon-optimized nucleic acid sequence does not comprise the nucleic acid sequence represented by SEQ ID NO: 2. In some embodiments, human SMN1 comprises the amino acid sequence represented by SEQ ID NO: 3.
[0013] In some embodiments, the endogenous SMN1 promoter is a human SMN1 promoter. In some embodiments, the endogenous SMN1 promoter comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:4 or 5. In some embodiments, the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:4. In some embodiments, the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:5.
[0014] In some embodiments, the recombinant adeno-associated virus (rAAV) vector comprises a promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and a transgene flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs), wherein the promoter is a constitutive promoter.In some embodiments, the promoter is a CB6 promoter.In some embodiments, the rAAV vector further comprises a CMV enhancer.
[0015] In some embodiments, the rAAV vector further comprises one or more miR-122 binding sites. In some embodiments, the one or more miR-122 binding sites are located between the codon-optimized nucleic acid sequence encoding human SMN1 and the 3' ITR. In some embodiments, the rAAV vector comprises a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NOs: 9-11. In some embodiments, at least one AAV ITR is an AAV2 ITR. In some embodiments, at least one AAV ITR is a mutated ITR (mTR). In some embodiments, the rAAV is a self-complementary AAV (scAAV).
[0016] In some embodiments, at least one AAV capsid protein is an AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9 capsid protein, or a variant thereof. In some embodiments, at least one AAV capsid protein is an AAV9 capsid protein. In some aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) comprising: (a) a self-complementary rAAV genome comprising (i) a 5' ITR; (ii) a human short SMN promoter comprising the nucleotide sequence of SEQ ID NO:5; (iii) a codon-optimized nucleic acid sequence encoding SMN1 represented by SEQ ID NO:1; (iv) a polyA tail; and (v) a 3' ITR; and (b) an AAV9 capsid protein. In some embodiments, the polyA tail is a rabbit globin polyA or a BGH polyA tail. In some embodiments, the rAAV further comprises one or more miR-122 binding sites.
[0017] In some aspects, the disclosure provides a pharmaceutical composition comprising a rAAV vector or rAAV described herein and a pharma- ceutically acceptable excipient. In some aspects, the disclosure provides a method of delivering a transgene to a cell, the method comprising administering to the cell an rAAV vector, an rAAV, or a pharmaceutical composition described herein. In some embodiments, the cell is a mammalian cell. In some embodiments, the cell is a human cell. In some embodiments, the cell is in a subject. In some embodiments, the subject has or is suspected of having spinal muscular atrophy (SMA).
[0018] In some aspects, the disclosure provides a method for preventing or treating spinal muscular atrophy (SMA) in a subject, the method comprising administering to the subject a rAAV vector, rAAV, or pharmaceutical composition described herein. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. In some embodiments, the subject has one or more mutations in the SMN1 gene. In some embodiments, the administering comprises a systemic or local injection. In some embodiments, the systemic injection comprises an intravenous injection. In some embodiments, the administering comprises an injection into the central nervous system (CNS) of the subject.
[0019] In some embodiments, the administration results in a reduced amount of dorsal root ganglion (DRG) toxicity in the subject compared to administration to the subject of an rAAV encoding wild-type SMN1. In some embodiments, the administration results in a reduced amount of dorsal root ganglion (DRG) toxicity in the subject compared to administration to the subject of an rAAV comprising a constative promoter operably linked to a wild-type SMN1 coding sequence. In some embodiments, the administration results in reduced liver toxicity in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1.
[0020] In some embodiments, administration results in a reduction in complications associated with SMA. In some embodiments, complications of SMA include pulmonary infections, spinal deformities (e.g., scoliosis, hip subluxation / dislocation), joint contractures, or respiratory failure. In some embodiments, administration results in improved survival in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1. [Brief description of the drawings]
[0021] [Figure 1]FIG. 1 shows a schematic diagram of the SMN1-encoding vector of the present disclosure. "scAAV-CB6-opt-SMN1" is a self-complementary AAV (scAAV) vector with a CB6 promoter and a codon-optimized SMN1 coding sequence. "SMNlp-SMN1" is a single-stranded AAV genome with 2.0 kb of the endogenous human SMN1 promoter and a codon-optimized SMN1 coding sequence (CDS). "ssAAV-opt-SMN1(MBL)" is a single-stranded AAV genome with 2.0 kb of the endogenous human SMN1 promoter, a synthetic MBL intron, and a codon-optimized SMN1 coding sequence (CDS). "SMNsp-SMN1" is a self-complementary AAV vector with 0.9 kb of the endogenous human SMN1 promoter and a codon-optimized SMN1 CDS. "Zolgensma" is a self-complementary AAV vector containing the CMV enhancer / chicken beta-actin promoter and wild-type human SMN1 CDS.
[0022] [Fig. 2A-2F]Figures 2A-2F show representative data for ssAAV9.opt-SMN1 and Zolgensma in SMNΔ7 mice. Figure 2A shows survival curves for SMNΔ7 mice treated with Zolgensma (2xE14 genome copies (GC) / kg) or three doses of SMNp-SMN1 rAAV (2xE14 genome copies (GC) / kg, 6.8xE13 GCS / kg, or 3.4xE13 GCS / kg); treatment with the same or 1 / 3 dose of ssAAV9.opt-SMN1 shows higher survival rates than mice treated with Zolgensma. Figures 2B and 2C show representative data showing that ssAAV9.opt-SMN1-treated mice show similar weight gain compared to Zolgensma-treated mice. Figure 2D shows survival curves of scAAV9.opt-SMN1 and Zolgensma in SMNΔ7 mice; treatment with the same or 1 / 3 dose of ssAAV9.opt-SMN1 shows higher survival rates than mice treated with Zolgensma. Figures 2E and 2F show representative data showing that ssAAV9.opt-SMN1-treated mice show similar weight gain compared to Zolgensma-treated mice.
[0023] [Figure 3A-3B] Figures 3A-3B show representative behavioral assay data from SMNΔ7 mice treated with scAAV9.opt-SMN1. Figure 3A shows that animals treated with scAAV9.opt-SMN1 are able to recover on their own from 5 days post-administration. Figure 3B shows representative data showing that all treated animals have functional muscles as measured by the rotarod test. [Figure 4A-4B]Figures 4A-4B show representative toxicological data. Figure 4A shows histological data indicating that high levels of SMN1 overexpression are toxic to liver cells. Briefly, AAV vectors were injected into animals at P0 via the facial vein at 5E+11 GC / mouse. Livers were harvested 8 days after injection. Liver damage was observed in the AAVsc-CB6-PI-SMN1 (6 / 6 animals) and Zolgensma (4 / 7 animals) vector treatment groups, but not in the control empty AAV9 (0 / 8 animals) or ssAAV9-opt-SMN1 (0 / 8) vector treatment groups. Figure 4B shows representative alanine aminotransferase (ALT) assay test results.
[0024] [Diagram 5] FIG. 5 shows a schematic diagram illustrating the recommended expression levels of vectors encoding SMN1. [Figures 6A-6D] Figures 6A-6D show representative data for SMNΔ7 mice treated with Zolgensma, SMNp-SMN1 rAAV, or SMNsp-SMN1 rAAV. Figure 6A shows the survival curves for SMNΔ7 mice treated with Zolgensma (5xE11 genome copies (GC)) or two doses of SMNp-SMN1 rAAV (5xE11 GC or 1.67xE11 GC). Figure 6B shows the weight gain for SMNΔ7 mice treated with Zolgensma (5xE11 GC) or two doses of SMNp-SMN1 rAAV (5xE11 GC or 1.67xE11 GC). Figure 6C shows survival curves for SMNΔ7 mice treated with Zolgensma (5xE11 GC) or three doses of SMNsp-SMN1 rAAV (5xE11 GC, 1.67xE11 GC, or 0.8xE11 GC). Figure 6D shows weight gain for SMNΔ7 mice treated with Zolgensma (5xE11 GC) or two doses of SMNsp-SMN1 rAAV (5xE11 GC or 1.67xE11 GC). Untreated control animals are also shown in each figure.
[0025] [Figure 7A-7D]Figures 7A-7D show that rAAV9sc-CMVen / CB-co-hSMN1 induced liver toxicity due to overexpression of hSMN1 in the liver. Figure 7A shows that mice receiving rAAV9sc-CMVen / CB-co-hSMN1 treatment via facial vein injection showed yellow skin. Figure 7B shows that liver toxicity was observed by liver histology in mice administered rAAV9sc-CMVen / CB-co-hSMN1. Figure 7C shows the number of animals with liver toxicity after rAAV9sc-CMVen / CB-co-hSMN treatment compared to the reference vector and untreated control (UC). Figure 7D shows SMN1 expression in the liver of mice treated with rAAV9sc-CMVen / CB-co-hSMN, reference vector, or untreated control.
[0026] [Figure 8A-8C] Figures 8A-8C show that incorporation of miR-122 binding sites into the CMVen / CB-co-hSMN vector suppresses SMN1 expression in the liver, thereby reducing liver toxicity. Figure 8A shows AAV vectors with and without miR-122 binding sites. Figure 8B shows that incorporation of miR-122 binding sites into the CMVen / CB-co-hSMN vector (CB6-PI-opt hSMN1-miR-122 BS) suppressed SMN1 expression in the liver. Figure 8C shows that mice treated with scAAV9-CB6-PI-opt hSMN1-miR-122 BS did not have liver toxicity compared to mice treated with rAAV9sc-CMVen / CB-co-hSMN1.
[0027] [Figure 9A-9L]Figures 9A-9L show that second generation AAV (AAVsc-SMNp-co-hSMN1) resulted in improved therapeutic outcomes in SMA animal models. Figure 9A shows that AAVsc-SMNp-co-hSMN1 resulted in higher expression efficiency in Neuro-2a cells compared to rAAV9sc-CMVEN / CB6-co-hSMN1. Figure 9B shows the experimental design of treating mice with AAVsc-SMNp-co-hSMN1 via facial vein injection, and mice were monitored daily after treatment. Figure 9C shows that mice treated with AAVsc-SMNsp-co-hSMN1 gained more weight than the reference vector group. Figure 9D shows that administration of AAVsc-SMNsp-co-hSMN1 vector significantly improved the lifespan of SMA mice. Figure 9E shows that AAVsc-SMNsp-co-hSMN1-treated SMA mice were healthy at 5 months of age. FIG. 9F shows that SMA mice treated with AAVsc-SMNsp-co-hSMN1 were able to recover on their own faster than the reference mice. FIG. 9G shows representative images of the transversus abdominis (TVA) muscle, showing the effect of treatment on the recovery of innervation of the neuromuscular junction (NMJ). FIG. 9H shows that the structure of the neuromuscular junction in AAVsc-SMNsp-co-hSMN1-treated mice was closer to that of wild-type mice and recovered better than the reference-treated SMA mice. FIG. 9I shows various stages of ear necrosis as one of the complications in SMA mice. FIG. 9J shows that treatment with AAVsc-SMNsp-co-hSMN1 mitigated the complications (ear necrosis as an example) in SMA mice. FIG. 9K-9L show immunoblot assays showing that AAVsc-SMNsp-co-hSMN1 is preferentially expressed in the central nervous system other than peripheral tissues. The expression pattern of this vector closely resembles the natural distribution of SMN as in healthy control animals.
[0028] [Figure 10]FIG. 10 shows representative survival curves of SMA mice that were untreated (NT), treated with the benchmark vector (BMK), or treated with scAAV9-SMNsp-hSMN1; mice treated with scAAV9-SMNsp-hSMN1 have a higher survival rate than untreated or BMK-treated mice.
[0029] Detailed Description Aspects of the present disclosure relate to compositions and methods for treating spinal muscular atrophy (SMA). The present disclosure is based in part on isolated nucleic acids and vectors (e.g., viral vectors, such as rAAV vectors) encoding SMN1. In some embodiments, SMN1 expression is driven by the native SMN1 promoter or a variant thereof. In some embodiments, the isolated nucleic acids and vectors of the present disclosure have reduced toxicity and / or increased transgene expression and / or reduced off-target tissue expression compared to previously described vectors encoding SMN.
[0030] Survival of Motor Neuron 1 (SMN1) Aspects of the present disclosure relate to compositions (e.g., isolated nucleic acids, vectors such as rAAV vectors, rAAV, etc.) encoding survival of motor neuron 1 (SMN1) protein. SMN1 protein is a component of a complex that catalyzes the assembly of small nuclear ribonucleoproteins (snRNPs) and plays a key role in splicing cellular pre-mRNA. Mutations in SMN1 and SMN2 are associated with spinal muscular atrophy (SMA), a severe neuromuscular disorder that results in loss of motor neurons and progressive muscle wasting. Spinal muscular atrophy (SMA) is a rare neuromuscular disorder that results in loss of motor neurons and progressive muscle wasting. It is usually diagnosed during infancy or early childhood and is the most common genetic cause of infant death if left untreated. It may also develop later in life and have a milder disease course thereafter. A common feature is progressive weakness of voluntary muscles, with the arms, legs, and respiratory muscles being affected first. Individuals with SMA can develop complications and associated problems including poor head control, difficulty swallowing, lung infections, spinal deformities (e.g., scoliosis, hip subluxation / dislocation), joint contractures, and respiratory failure.
[0031] The age at onset and severity of symptoms form the basis of the existing classification of spinal muscular atrophy into different types. Spinal muscular atrophy is caused by abnormalities (mutations) in the SMN1 gene, which codes for SMN, a protein required for the survival of motor neurons. Loss of these neurons in the spinal cord disrupts signaling between the brain and skeletal muscles. Another gene, SMN2, is considered a disease-modifying gene because more copies of SMN2 usually result in a milder disease course. Diagnosis of SMA is based on symptoms and confirmed by genetic testing.
[0032] The natural course of the disease varies from death within the first few weeks of life in the most acute cases to a normal life expectancy in long-form SMA. Drugs that target the genetic cause of the disease include nusinersen, risdiplam, and the gene therapy drug onasemnogene-abeparvovec. Symptomatic treatments include physical therapy, occupational therapy, respiratory support, nutritional support, orthopedic interventions, and mobility assistance.
[0033] In humans, SMN1 is encoded by the SMN1 gene, e.g., represented by NCBI reference sequence numbers NM_000344, NM_001297715, and NM_022874. In some embodiments, the SMN1 protein comprises an amino acid sequence represented by any of NCBI reference sequence numbers NP_059107, NP_075013, NP_075014, NP_075015, NP_000335. In some embodiments, the SMN1 protein comprises an amino acid sequence represented by SEQ ID NO:3. In some embodiments, the SMN1 protein comprises an amino acid sequence at least 50%, 60%, 70%, 75%, 80%, 90%, 95%, or 99% identical to the amino acid sequence represented by SEQ ID NO:3.
[0034] In some aspects, the disclosure relates to an isolated nucleic acid comprising a codon-optimized (e.g., optimized for increased expression in human cells, reduced toxicity, reduced immunogenicity, etc.) nucleic acid sequence encoding an SMN1 protein. In some embodiments, the isolated nucleic acid encoding an SMN1 protein comprises a nucleic acid sequence that is at least 70%, 75%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented in SEQ ID NO:1. In some embodiments, the isolated nucleic acid encoding an SMN1 protein comprises the nucleic acid sequence represented in SEQ ID NO:1. In some embodiments, the isolated nucleic acid encoding an SMN1 protein consists of the nucleic acid sequence represented in SEQ ID NO:1.
[0035] In some embodiments, the isolated nucleic acid encoding the SMN1 protein includes at least one (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, 100, 150, 200, 250, or more) nucleotide substitutions, insertions, deletions, or any combination thereof, relative to the nucleic acid sequence encoding wild-type SMN1, such as the nucleic acid sequence represented by SEQ ID NO:2.
[0036] A "nucleic acid" sequence refers to a DNA or RNA sequence. In some embodiments, the proteins and nucleic acids of the present disclosure are isolated. As used herein, the term "isolated" means artificially produced. As used herein, the term "isolated" with respect to a nucleic acid means: (i) amplified in vitro, for example by polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, for example by cleavage and gel separation; or (iv) synthesized, for example by chemical synthesis. An isolated nucleic acid is one that can be readily manipulated by recombinant DNA techniques that are well known in the art. Thus, a nucleotide sequence contained in a vector in which the 5' and 3' restriction sites are known, or for which the polymerase chain reaction (PCR) primer sequences are disclosed, is considered isolated, but a nucleic acid sequence that exists naturally in a natural host is not considered isolated. An isolated nucleic acid can be, but need not be, substantially purified. For example, a nucleic acid isolated within a cloning vector or expression vector is not pure in that it may represent only a small portion of the material in the cell in which it resides. However, such nucleic acids are isolated, as the term is used herein, because they are readily manipulable by standard techniques known to those of skill in the art. As used herein with respect to a protein or peptide, the term "isolated" refers to a protein or peptide that has been isolated from its natural environment or that has been artificially produced (e.g., by chemical synthesis, recombinant DNA technology, etc.).
[0037] The isolated nucleic acid of the present disclosure may be a recombinant adeno-associated virus (AAV) vector (rAAV vector). In some embodiments, the isolated nucleic acid described in the present disclosure comprises a region (e.g., a first region) comprising a first adeno-associated virus (AAV) inverted terminal repeat (ITR) or a variant thereof. The isolated nucleic acid (e.g., a recombinant rAAV vector) may be packaged in a capsid protein and administered to a subject and / or delivered to a selected target cell. A "recombinant AAV (rAAV) vector" typically consists, at a minimum, of a transgene and its regulatory sequences, as well as 5' and 3' AAV inverted terminal repeats (ITRs). The transgene may comprise, for example, a region encoding a protein and / or an expression control sequence (e.g., a polyA tail), as described elsewhere in this disclosure.
[0038] Generally, the ITR sequences are about 145 bp in length. Preferably, substantially the entire ITR-encoding sequences are used in the molecule, although some minor modification of these sequences is tolerated. The ability to modify these ITR sequences is within the skill of the art. (See, e.g., "Molecular Cloning. A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory, New York (1989); and K. Fisher et al., J Virol., 70:520 532 (1996)). An example of such a molecule used in the present disclosure is a "cis-acting" plasmid containing a transgene, in which a selected transgene sequence and associated regulatory elements are flanked by 5' and 3' AAV ITR sequences. The AAV ITR sequences may be obtained from any known AAV, including currently identified mammalian AAV types. In some embodiments, the isolated nucleic acid further comprises a region (e.g., a second region, a third region, a fourth region, etc.) that includes a second AAV ITR. In some embodiments, the isolated nucleic acid encoding the transgene is flanked by AAV ITRs (e.g., in the orientation of 5'-ITR-transgene-ITR-3'). In some embodiments, the AAV ITRs are AAV2 ITRs. In some embodiments, at least one AAV ITR is a truncated AAV ITR (e.g., a mutant ITR also called mTR), such as a ΔITR as described in McCarty (2008) Molecular Therapy 16(10): 1648-1656.
[0039] In addition to the major elements identified above for recombinant AAV vectors, the vector also includes conventional control elements operably linked to the transgene elements in a manner that allows transcription, translation and / or expression in cells transfected with the vector produced by the present disclosure or infected with the virus. As used herein, "operably linked" sequences include both expression control sequences contiguous with the gene of interest and expression control sequences acting in trans or at a distance to control the gene of interest. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation (polyA) signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., Kozak consensus sequences); sequences that enhance protein stability; and, if necessary, sequences that enhance secretion of the encoded product. Numerous expression control sequences, including promoters that are natural, constitutive, inducible and / or tissue-specific, are known in the art and can be utilized.
[0040] As used herein, a nucleic acid sequence (e.g., a coding sequence) and a regulatory sequence are said to be "operably" linked when they are covalently linked in such a way that the expression or transcription of the nucleic acid sequence is under the influence or control of the regulatory sequence. If it is desired that the nucleic acid sequence be translated into a functional protein, the two DNA sequences are said to be operably linked if induction of a promoter in the 5'regulatory sequence results in transcription of the coding sequence, and the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frameshift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably linked to a nucleic acid sequence if it is capable of effecting transcription of that DNA sequence such that the resulting transcript may be translated into a desired protein or polypeptide. Similarly, two or more coding regions are operably linked when they are linked such that their transcription from a common promoter results in the expression of two or more proteins translated in frame. In some embodiments, operably linked coding sequences result in a fusion protein.
[0041] The region containing the transgene (such as, for example, a transgene encoding an SMN1 protein) can be located in any suitable location of the isolated nucleic acid that will allow for expression of at least one transgene, selectable marker protein, or reporter protein. It should be understood that when a transgene encodes multiple transgene products (e.g., an SMN1 protein and another protein or interfering nucleic acid), each gene product can be located at any suitable position within the transgene. For example, a nucleic acid encoding a first polypeptide can be located in an intron of the transgene, and a nucleic acid sequence encoding a second polypeptide can be located in another untranslated region (e.g., between the last codon of the protein coding sequence and the first base of the polyA signal of the transgene).
[0042] "Promoter" refers to a DNA sequence that is recognized by the synthetic machinery of a cell or introduced synthetic machinery necessary to initiate the specific transcription of a gene. The phrases "operably linked," "operably positioned," "under control," or "under transcriptional control" mean that the promoter is in the correct location and orientation relative to the nucleic acid to control the initiation of RNA polymerase and expression of the gene.
[0043] In the case of nucleic acids encoding proteins, polyadenylation sequences are generally inserted after the transgene sequence and before the 3'AAV ITR sequence. The rAAV constructs useful in this disclosure may also contain an intron, desirably located between the promoter / enhancer sequence and the transgene. One possible intron sequence is derived from SV-40 and is called the SV-40 T intron sequence. In some embodiments, the intron is a non-natural intron or a synthetic intron (e.g., the MBL intron). Another vector element that may be used is an internal ribosome entry site (IRES). IRES sequences are used to produce two or more polypeptides from a single gene transcript. IRES sequences will be used to produce proteins that contain two or more polypeptide chains. Selection of these and other common vector elements is routine, and many such sequences are available [see, e.g., Sambrook et al., and references cited therein, e.g., pages 3.18 3.26 and 16.17 16.27, and Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989]. In some embodiments, the foot and mouth disease virus 2A sequence is included in the polyprotein, which is a small peptide (approximately 18 amino acids long) that has been shown to mediate polyprotein cleavage (Ryan, MD et al., EMBO,1994; 4:928-933; Mattion, NM et al., J Virology, November 1996; p.8124-8127; Furler, S et al., Gene Therapy,2001;8:864-873; and Halpin, C et al., The Plant Journal,1999;4:453-459).The cleavage activity of the 2A sequence has been previously demonstrated in artificial systems including plasmids and gene therapy vectors (AAV and retroviruses) (Ryan, MD et al., EMBO,1994;4:928-933; Mattion, NM et al., J Virology, November 1996;p.8124-8127; Furler, S et al., Gene Therapy,2001;8:864-873; and Halpin, C et al., The Plant Journal,1999;4:453-459; de Felipe, P et al., Gene Therapy,1999;6:198-208; de Felipe, P et al., Human Gene Therapy,2000;11:1921-1931.; and Klump, H et al., Gene Therapy,2001;8:811-817).
[0044] Examples of constitutive promoters include, without limitation, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer) [see, e.g., Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter [Invitrogen]. In some embodiments, the promoter is an RNA pol II promoter. In some embodiments, the promoter is an RNA pol III promoter, such as U6 or H1. In some embodiments, the promoter is an RNA pol II promoter. In some embodiments, the promoter is a chicken β-actin (CBA) promoter. In some embodiments, the promoter comprises a U1a promoter.
[0045] Inducible promoters allow the regulation of gene expression and can be regulated by exogenously supplied compounds, environmental factors such as temperature, or the presence of certain physiological conditions, such as acute phase, certain differentiation states of cells, or only in replicating cells. Inducible promoters and induction systems are available from a variety of commercial sources, including, but not limited to, Invitrogen, Clontech, and Ariad. Many other systems have been described and can be easily selected by those skilled in the art. Examples of inducible promoters regulated by an exogenously supplied promoter include the zinc-inducible sheep metallothionine (MT) promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV) promoter, the T7 polymerase promoter system (WO 98 / 10088); the ecdysone insect promoter (No et al., Proc. Natl. Acad. Sci. USA, 93:3346-3351 (1996)), the tetracycline repressible system (Gossen et al., Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)), the tetracycline inducible system (Gossen et al., Science, 268:1766-1769 (1995), and also Harvey et al., Curr. Opin. Chem. Biol., 2:512-518 (1996)). (1998)), the RU486 inducible system (Wang et al., Nat. Biotech., 15:239-243 (1997) and Wang et al., Gene Ther., 4:432-441 (1997)), and the rapamycin inducible system (Magari et al., J. Clin. Invest., 100:2865-2872 (1997)). Still other types of inducible promoters that may be useful in this context are those that are regulated by specific physiological conditions, such as temperature, acute phase, a specific differentiation state of the cell, or only in replicating cells.
[0046] Aspects of the disclosure relate to isolated nucleic acids and rAAV vectors comprising a nucleic acid sequence encoding SMN1 (e.g., a codon-optimized nucleic acid sequence encoding SMN1) operably linked to a native promoter. In some embodiments, the native promoter comprises the human SMN1 promoter or a variant thereof. In some embodiments, the human SMN1 promoter comprises a nucleic acid sequence represented by SEQ ID NO:4. In some embodiments, the promoter comprises a portion of the human SMN1 promoter comprising a nucleic acid sequence represented by SEQ ID NO:5 (i.e., a short hSMN1 promoter). In some embodiments, the human SMN1 promoter or a variant thereof comprises a nucleic acid sequence that is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NO:4 or the nucleic acid sequence represented by SEQ ID NO:5. Human SMN1 promoters are generally known in the art and are described, for example, in Echaniz-Laguna et al., Am. J. Hum. Genet. 64:1365-1370, 1999. When it is desired that the expression of the transgene mimics the native expression (e.g., expressing physiological levels of hSMN1 expression in the appropriate cell type), the native promoter may be preferred. The native promoter may be used when the expression of the transgene must be regulated temporally or developmentally, or tissue-specifically, or in response to a specific transcriptional stimulus. Without wishing to be bound by any theory, the use of the human SMN1 promoter in the isolated nucleic acids and rAAV vectors described herein regulates the expression of human SMN1 protein from the vector and reduces toxicity in the subject, such as dorsal root ganglion (DRG) toxicity or liver toxicity, compared to the expression of human SMN1 protein from isolated nucleic acids and rAAV vectors containing other promoters, such as the CMV promoter, chicken beta actin (CBA) promoter, CB6 promoter, etc.In further embodiments, other native expression control elements, such as enhancer elements, polyadenylation sites, and / or Kozak consensus sequences, can also be used to mimic native expression.
[0047] In some embodiments, the regulatory sequence confers tissue-specific gene expression capability. In some cases, the tissue-specific regulatory sequence binds to tissue-specific transcription factors that induce transcription in a tissue-specific manner. Such tissue-specific regulatory sequences (e.g., promoters, enhancers, etc.) are well known in the art. Exemplary tissue-specific regulatory sequences include, but are not limited to, the following tissue-specific promoters: retinoschisin proximal promoter, interphotoreceptor retinoid-binding protein enhancer (RS / IRBPa), rhodopsin kinase (RK), liver-specific thyroxine-binding globulin (TBG) promoter, insulin promoter, glucagon promoter, somatostatin promoter, pancreatic polypeptide (PPY) promoter, synapsin 1 (Syn) promoter, creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, α-myosin heavy chain (α-MHC) promoter, or cardiac troponin T (cTnT) promoter.Other exemplary promoters include, among others, those apparent to one of skill in the art: beta actin promoter, hepatitis B virus core promoter, Sandig et al., Gene Ther., 3:1002-9 (1996); alpha fetoprotein (AFP) promoter, Arbuthnot et al., Hum. Gene Ther., 7:1503-14 (1996)), bone osteocalcin promoter (Stein et al., Mol. Biol. Rep., 24:185-96 (1997)); bone sialoprotein promoter (Chen et al., J. Bone Miner. Res., 11:654-64 (1996)), CD2 promoter (Hansal et al., J. Immunol., 161:1063-8 (1998)); immunoglobulin heavy chain promoter, T cell receptor alpha chain promoter, neuronal such as the neuron-specific enolase (NSE) promoter (Andersen et al., J. Immunol., 161:1063-8 (1998)). al., Cell. Mol. Neurobiol., 13:503-15 (1993)), the neurofilament light chain gene promoter (Piccioli et al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and the neuron-specific vgf gene promoter (Piccioli et al., Neuron, 15:373-84 (1995)).
[0048] In some embodiments, the promoter preferentially drives transgene expression in certain tissues. In some embodiments, the disclosure provides a nucleic acid comprising a tissue-specific promoter operably linked to a transgene. As used herein, a "tissue-specific promoter" refers to a promoter that preferentially regulates (e.g., drives or upregulates) gene expression in a particular cell type relative to other cell types. A cell type-specific promoter can be specific to any cell type, such as central nervous system (CNS) cells, liver cells (e.g., hepatocytes), cardiac cells, muscle cells, etc. In some embodiments, the tissue-specific promoter is a promoter specific to muscle tissue or cells. Examples of CNS-specific promoters include, but are not limited to, synapsin (Syn), GFAP, Ca2 + / Calmodulin-dependent protein kinase II (hCAMKII) and others.
[0049] In some aspects, the present disclosure relates to an isolated nucleic acid comprising a transgene encoding one or more miRNA binding sites. Without wishing to be bound by any particular theory, incorporating miRNA binding sites into gene expression constructs allows for the regulation of transgene expression (e.g., inhibition of transgene expression) in cells and tissues in which the corresponding miRNA is expressed. In some embodiments, incorporating one or more miRNA binding sites into a transgene allows for the detargeting of transgene expression in a cell type-specific manner. In some embodiments, one or more miRNA binding sites are located in the 3' untranslated region (3'UTR) of a transgene, for example, between the last codon and polyA sequence of the nucleic acid sequence encoding one or more complement control proteins described herein. In some embodiments, the rAAV vectors described herein comprise a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NOs:6-8.
[0050] In some embodiments, expression of the transgene causes overexpression of the transgene in the liver, resulting in liver toxicity (see, e.g., Hinderer et al., Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN, Volume: 29 Issue 3, 285-298: March 1, 2018). In some embodiments, to reduce liver toxicity, the AAV vector comprises a transgene that comprises one or more (e.g., 1, 2, 3, 4, 5, or more) miRNA binding sites that detarget expression of the transgene from liver cells. For example, in some embodiments, the transgene comprises one or more miR-122 binding sites. In some embodiments, the rAAV vectors described herein comprise one or more miR-122 binding sites. In some embodiments, an rAAV vector containing a miR-122 binding site comprises a nucleic acid sequence that is at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to SEQ ID NOs:9-11.
[0051] In some embodiments, the transgene comprises one or more (e.g., 1, 2, 3, 4, 5, or more) miRNA binding sites that detarget expression of the transgene from immune cells (e.g., antigen presenting cells (APCs), such as macrophages, dendrites, etc.). Incorporation of a miRNA binding site for an immune-related miRNA can detarget expression of the transgene (e.g., one or more inhibitory nucleic acids) from antigen presenting cells, thereby reducing or eliminating an immune response (cellular and / or humoral) generated in a subject against the transgene product, as described, for example, in US 2018 / 0066279, the entire contents of which are incorporated herein by reference.
[0052] As used herein, "immune-related miRNA" refers to miRNAs that are preferentially expressed in cells of the immune system, such as antigen-presenting cells (APCs). In some embodiments, the immune-related miRNA is an miRNA expressed in immune cells that exhibits at least 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold higher expression levels in immune cells compared to non-immune cells (e.g., control cells such as HeLa cells, HEK293 cells, mesenchymal cells, etc.). In some embodiments, the cells of the immune system (immune cells) in which the immune system-related miRNA is expressed are B cells, T cells, killer T cells, helper T cells, γδ T cells, dendritic cells, macrophages, monocytes, vascular endothelial cells, or other immune cells. In some embodiments, the immune system cell is a B cell that expresses one or more of the following markers: B220, BLAST-2 (EBVCS), Bu-1, CD19, CD20 (L26), CD22, CD24, CD27, CD57, CD72, CD79a, CD79b, CD86, chB6, D8 / 17, FMC7, L26, M17, MUM-1, Pax-5 (BSAP), and PC47H. In some embodiments, the immune system cells are T cells expressing one or more of the following markers: ART2, CD1a, CD1d, CD11b (Mac-1), CD134 (OX40), CD150, CD2, CD25 (Interleukin 2 receptor alpha), CD3, CD38, CD4, CD45RO, CD5, CD7, CD72, CD8, CRTAM, FOXP3, FT2, GPCA, HLA-DR, HML-1, HT23A, Leu-22, Ly-2, Ly-m22, MICG, MRC OX 8, MRC OX-22, OX40, PD-1 (Programmed Death-1), RT6, TCR (T cell receptor), Thy-1 (CD90), TSA-2 (Thymic Common Ag-2).In some embodiments, the immune-related miRNA is selected from: miR-15a, miR-16-1, miR-17, miR-18a, miR-19a, miR-19b-1, miR-20a, miR-20a, miR-21, miR-29a / b / c, miR-30b, miR-31, miR-34a, miR-92a-1, miR-106a, miR-125a / b, miR-142-3p, miR-146a, miR-150, miR-155, miR-181a, miR-223 and miR-424, miR-221, miR-222, let-7i, miR-148, and miR-152. In some embodiments, the transgene described herein comprises one or more binding sites for miR-142.
[0053] Recombinant adeno-associated virus (rAAV) In some aspects, the present disclosure provides isolated adeno-associated viruses (AAVs). As used herein, the term "isolated" in reference to AAV refers to AAV that is artificially produced or obtained. Isolated AAV can be produced using recombinant methods. Such AAV is referred to herein as "recombinant AAV". Recombinant AAV (rAAV) preferably has tissue-specific targeting function, thus the transgene of rAAV is specifically delivered to one or more predefined tissues (e.g., muscle tissue, eye tissue, neuron, etc.). AAV capsid is an important factor in determining these tissue-specific targeting functions (e.g., tissue tropism). Thus, rAAV with a capsid suitable for the tissue to be targeted can be selected.
[0054] In some embodiments, the rAAV of the disclosure comprises a nucleotide sequence represented by SEQ ID NO:1, 6, or 7, or encodes a protein having an amino acid sequence represented by SEQ ID NO:3. In some embodiments, the rAAV of the disclosure comprises a nucleotide sequence that is 99% identical, 95% identical, 90% identical, 85% identical, 80% identical, 75% identical, 70% identical, 65% identical, 60% identical, 55% identical, or 50% identical to a nucleotide sequence represented by SEQ ID NO:1, 6-11.
[0055] In some aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV) comprising: (a) a self-complementary rAAV genome comprising (i) a 5' ITR; (ii) a human short SMN promoter comprising the nucleotide sequence of SEQ ID NO:5; (iii) a codon-optimized nucleic acid sequence encoding SMN1 represented by SEQ ID NO:1; (iv) a polyA tail; and (v) a 3' ITR; and (b) an AAV9 capsid protein. In some embodiments, the polyA tail is a rabbit globin polyA or a BGH polyA tail. In some embodiments, the rAAV further comprises one or more miR-122 binding sites.
[0056] Methods for obtaining recombinant AAV with desired capsid proteins are well known in the art. (See, e.g., US 2003 / 0138772, the contents of which are incorporated herein by reference in their entirety). Typically, the methods involve culturing a host cell containing nucleic acid sequences encoding AAV capsid proteins; a functional rep gene; a recombinant AAV vector composed of AAV inverted terminal repeats (ITRs) and a transgene; and sufficient helper functions to allow packaging of the recombinant AAV vector into AAV capsid proteins. In some embodiments, the capsid proteins are structural proteins encoded by the cap gene of AAV. In some embodiments, AAV contains three capsid proteins, virion proteins 1 to 3 (named VP1, VP2 and VP3), all of which are transcribed from a single cap gene via alternative splicing. In some embodiments, the molecular weights of VP1, VP2 and VP3 are about 87 kDa, about 72 kDa and about 62 kDa, respectively. In some embodiments, upon translation, capsid protein forms a spherical 60-mer protein shell around the viral genome. In some embodiments, the function of capsid protein is to protect the viral genome, deliver the genome, and interact with the host. In some aspects, capsid protein delivers the viral genome to the host in a tissue-specific manner.
[0057] In some embodiments, the AAV capsid protein has tropism for central nervous system (CNS) tissue. In some embodiments, the AAV capsid protein targets neuronal cell types, astrocytes, oligodendrocytes, glial cells, etc. In some embodiments, the AAV capsid protein is an AAV serotype selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAVrh8, AAV9, AAV10, AAVrh10, AAV.PHP-eB, AAVrh39, AAVrh43, and any variants of the above. In some embodiments, the rAAV comprises AAV9 capsid protein.
[0058] In some embodiments, the rAAV vector or rAAV particle comprises a mutant ITR that lacks a functional terminal release site (TRS). The term "lack of a terminal release site" can refer to an AAV ITR that contains a mutation that destroys the function of the terminal release site (TRS) of the ITR (e.g., a sense mutation such as a non-synonymous mutation or a missense mutation), or a truncated AAV ITR that lacks the nucleic acid sequence that codes for a functional TRS (e.g., ΔTRS ITR). Without wishing to be bound by any particular theory, an rAAV vector that contains an ITR that lacks a functional TRS generates a self-complementary rAAV vector (scAAV or scrAAV vector), for example, as described in McCarthy (2008) Molecular Therapy 16(10):1648-1656.
[0059] The components to be cultured in the host cell to package the rAAV vector into an AAV capsid may be provided in trans to the host cell. Alternatively, any one or more of the necessary components (e.g., recombinant AAV vector, rep sequences, cap sequences, and / or helper functions) may be provided by a stable host cell that has been engineered to contain one or more of the necessary components using methods known to those of skill in the art. Most suitably, such a stable host cell will contain the necessary components under the control of an inducible promoter. However, the necessary components may be under the control of a constitutive promoter. Examples of suitable inducible and constitutive promoters are provided herein in the discussion of suitable regulatory elements for use with the transgene. In yet another alternative, the selected stable host cell may contain selected components under the control of a constitutive promoter and other selected components under the control of one or more inducible promoters. For example, a stable host cell may be generated that is derived from 293 cells (which contain E1 helper functions under the control of a constitutive promoter), but contains rep and / or cap proteins under the control of an inducible promoter. Still other stable host cells may be generated by those of skill in the art.
[0060] In some embodiments, the present disclosure relates to a host cell that contains a nucleic acid comprising a codon-optimized coding sequence that encodes a transgene (e.g., SMN1). A "host cell" refers to any cell that carries or is capable of carrying a substance of interest. In many cases, the host cell is a mammalian cell. In some embodiments, the host cell is a neuron. A host cell can be used as a recipient of AAV helper constructs, AAV minigene plasmids, accessory function vectors, or other introduced DNA in connection with the production of recombinant AAV. The term encompasses the progeny of the original transfected cell. Thus, as used herein, "host cell" may also refer to a cell that has been transfected with an exogenous DNA sequence. It is understood that the progeny of a single parent cell may not necessarily be completely identical in morphology or genomic or total DNA complement to the original parent due to natural, accidental, or deliberate mutations. In some embodiments, the host cell is a mammalian cell, a yeast cell, a bacterial cell, an insect cell, a plant cell, or a fungal cell. In some embodiments, the host cell is a central nervous system cell, such as a neuron or a glial cell.
[0061] The recombinant AAV vectors, rep sequences, cap sequences, and helper functions useful for producing the rAAV of the present disclosure may be delivered to the packaging host cell using any suitable genetic element (vector). The selected genetic element may be delivered by any suitable method, including those described herein. The methods used to construct any embodiment of the present disclosure are known to those skilled in the art of nucleic acid manipulation and include genetic engineering, recombinant engineering, and synthetic techniques. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, NY. Similarly, methods for producing rAAV virions are well known, and the selection of a suitable method is not a limitation of the disclosure. See, for example, K. Fisher et al., J. Virol., 70:520-532 (1993), and U.S. Patent No. 5,478,745.
[0062] In some embodiments, recombinant AAV can be produced using triple transfection method (described in detail in US Pat. No. 6,001,650). Typically, recombinant AAV is produced by transfecting a host cell with an AAV vector (including a transgene flanked by ITR elements) packaged into AAV particles, an AAV helper function vector, and an auxiliary function vector. The AAV helper function vector encodes "AAV helper function" sequences (e.g., rep and cap) that function in trans for replication and encapsidation of propagating AAV. Preferably, the AAV helper function vector supports efficient AAV vector production without producing any detectable wild-type AAV virions (e.g., AAV virions containing functional rep and cap genes). Non-limiting examples of vectors suitable for use in the present disclosure include pHLP19 described in US Pat. No. 6,001,650 and pRep6cap6 vector described in US Pat. No. 6,156,303, both of which are incorporated herein by reference in their entirety. The accessory function vector encodes nucleotide sequences for non-AAV derived viral and / or cellular functions (e.g., "accessory functions") on which AAV depends for replication. Accessory functions include functions necessary for AAV replication, including, but not limited to, portions involved in activation of AAV gene transcription, stage-specific AAV mRNA splicing, AAV DNA replication, synthesis of cap expression products, and AAV capsid assembly. Viral-based accessory functions can be derived from any of the known helper viruses, such as adenovirus, herpesvirus (other than herpes simplex virus type 1), and vaccinia virus.
[0063] In some aspects, the present disclosure provides a transfected host cell. The term "transfection" is used to refer to the uptake of foreign DNA by a cell, and a cell is "transfected" when foreign DNA is introduced inside the cell membrane. Numerous transfection techniques are generally known in the art. See, for example, Graham et al. (1973) Virology, 52:456, Sambrook et al. (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981) Gene 13:197. Such techniques can be used to introduce one or more exogenous nucleic acids, such as nucleotide integration vectors and other nucleic acid molecules, into a suitable host cell.
[0064] As used herein, the term "recombinant cell" refers to a cell into which an exogenous DNA segment has been introduced, such as a DNA segment that results in the transcription of a biologically active polypeptide or the production of a biologically active nucleic acid, such as RNA. As used herein, the term "vector" encompasses any genetic element, such as a plasmid, phage, transposon, cosmid, chromosome, artificial chromosome, virus, virion, etc., that can replicate and transfer genetic sequences between cells when associated with appropriate control elements. In some embodiments, the vector is a viral vector, such as an rAAV vector, a lentiviral vector, an adenoviral vector, or a retroviral vector. Thus, the term encompasses cloning and expression vehicles, as well as viral vectors. In some embodiments, the vector includes a baculoviral vector, which is useful for producing viral particles in certain insect cells (e.g., SF9 cells). In some embodiments, it is contemplated that a useful vector is one in which the nucleic acid segment to be transcribed is under the transcriptional control of a promoter.
[0065] Delivery of transgenes to tissues The isolated nucleic acid, rAAV and composition of the present disclosure may be delivered to a subject as a composition according to any suitable method known in the art.For example, rAAV, preferably suspended in a physiologically compatible carrier (e.g., in a composition), can be administered to a subject, i.e., a host animal, such as a human, mouse, rat, cat, dog, sheep, rabbit, horse, cow, goat, pig, guinea pig, hamster, chicken, turkey, or non-human primate (e.g., macaque).In some embodiments, the host animal does not include a human.In some embodiments, the subject is a human.
[0066] Delivery of rAAV can be, for example, by intramuscular injection or injection into muscle tissue or cells of a subject.As used herein, "muscle tissue" refers to any tissue derived from or contained in skeletal muscle, smooth muscle, or cardiac muscle of a subject.Non-limiting examples of muscle tissue include skeletal muscle, smooth muscle, cardiac muscle, myocyte, sarcomere, myofibril, etc.
[0067] Administration into the bloodstream can be by injection into a vein, artery, or any other vascular conduit.In some embodiments, rAAV is administered into the bloodstream by isolated limb perfusion, a technique well known in the surgical arts, which essentially allows the skilled artisan to isolate the limb from the general circulation before administration of rAAV virions.A variation of the isolated limb perfusion technique described in U.S. Patent No. 6,177,403 can also be used by the skilled artisan to administer virions into the vasculature of an isolated limb, potentially enhancing transduction into muscle cells or tissues.
[0068] Aspects of the present disclosure relate to compositions comprising a recombinant AAV comprising a nucleic acid encoding a capsid protein and a transgene, wherein the transgene comprises a codon-optimized nucleic acid sequence encoding an SMN1 protein. In some embodiments, the nucleic acid further comprises an AAV ITR. In some embodiments, the composition further comprises a pharma- ceutically acceptable carrier. The compositions of the present disclosure may include rAAV alone or in combination with one or more other viruses (e.g., a second rAAV carrying and encoding one or more different transgenes). In some embodiments, the composition includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more rAAVs, each carrying one or more different transgenes.
[0069] Suitable carriers can be easily selected by those skilled in the art, taking into consideration the indications for which rAAV is directed.For example, one suitable carrier includes saline, which can be formulated with various buffers (e.g., phosphate-buffered saline).Other exemplary carriers include sterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran, agar, pectin, peanut oil, sesame oil and water.The selection of carriers is not limiting of the present disclosure.
[0070] Optionally, the compositions of the present disclosure may contain other conventional pharmaceutical ingredients, such as preservatives or chemical stabilizers, in addition to rAAV and carriers.Suitable exemplary preservatives include chlorobutanol, potassium sorbate, sorbic acid, sulfur dioxide, propyl gallate, parabens, ethyl vanillin, glycerin, phenol and parachlorophenol, and poloxamers (non-ionic surfactants), such as Pluronic F-68.Suitable chemical stabilizers include gelatin and albumin.
[0071] rAAV is administered in an amount sufficient to transfect the cells of desired tissue and provide sufficient levels of gene transfer and expression without undue adverse effects.Conventional and pharmacologic acceptable administration routes include, but are not limited to, direct delivery to selected organ (e.g., intraportal delivery to liver), intraocular injection, subretinal injection, oral, inhalation (including intranasal and intratracheal delivery), intravenous, intramuscular, subcutaneous, intradermal, intratumoral, and other parenteral administration routes.If desired, administration routes may be combined.
[0072] The dose of rAAV virion required to achieve a particular "therapeutic effect", e.g., a unit dose in genome copies per kilogram of body weight (GC / kg), will vary based on several factors, including, but not limited to, the route of administration of the rAAV virion, the level of gene or RNA expression required to achieve the therapeutic effect, the particular disease or disorder being treated, and the stability of the gene or RNA product. One of skill in the art can readily determine the dose range of rAAV virion for treating a patient with a particular disease or disorder based on the factors described above, as well as other factors well known in the art. In some embodiments, the rAAV described herein is administered at a dose of about 10 9 ~10 16 The subject is administered a volume ranging from about 1 ml to about 100 ml containing about 10 genome copies. 11 ~10 13 Administer a dosage of rAAV genome copies.
[0073] The effective amount of rAAV is sufficient to target and infect animal and target the tissue of interest.In some embodiments, an effective amount of rAAV is administered to subject in the presymptomatic stage of degenerative disease.In some embodiments, rAAV or composition is administered to subject after showing one or more signs or symptoms of degenerative disease.
[0074] The effective amount of rAAV may also depend on the mode of administration. For example, when targeting muscle tissue (e.g., muscle cells) by intramuscular or subcutaneous injection, in some cases a different dose (e.g., higher or lower dose) may be required than when targeting muscle tissue in another manner (e.g., systemic administration, local administration, etc.). In some embodiments, intramuscular injection (IM) of rAAV with a particular serotype (e.g., AAV2, AAV6, AAV9, etc.) mediates efficient transduction of muscle cells. Thus, in some embodiments, the injection is intramuscular injection (IM). In some embodiments, the injection is systemic administration (e.g., intravenous injection). In some cases, the rAAV is administered multiple times. In some embodiments, the administration is systemic administration. In some embodiments, the systemic administration includes intravenous administration. In some embodiments, the administration is local administration to the central nervous system, for example, by intracerebral injection, intrathecal injection, intracranial injection, etc.
[0075] In some embodiments, the rAAV composition is particularly effective when high rAAV concentrations are present (e.g., about 10 13 GC / mL or more) and is formulated to reduce aggregation of AAV particles in the composition. Methods for reducing rAAV aggregation are well known in the art and include, for example, adding detergents, adjusting pH, adjusting salt concentration, etc. (See, e.g., Wright et al., Molecular Therapy (2005) 12, 171-178, the contents of which are incorporated herein by reference.) The formulation of pharma- ceutically acceptable excipient and carrier solutions is well known to those skilled in the art, as is the development of appropriate dosing and treatment regimens for use with the particular compositions described herein in the various treatment regimens.
[0076] Typically, these preparations may contain at least about 0.1% of active compound, although of course the percentage of active ingredient may vary and may conveniently be from about 1 or 2% to about 70% or 80% or more by weight or volume of the total formulation. Of course, the amount of active compound in each therapeutically useful composition may be prepared so that an appropriate dosage is obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, shelf life of the product, as well as other pharmacological considerations, are contemplated by those skilled in the art of preparing such pharmaceutical preparations, and therefore various dosages and treatment regimes may be desirable.
[0077] In certain circumstances, it may be desirable to deliver the rAAV-based therapeutic construct in the appropriately formulated pharmaceutical composition disclosed herein either intraocularly, subretinally, subcutaneously, intrapancreatically, intranasally, parenterally, intravenously, intramuscularly, intrathecally, orally, intraperitoneally, or by inhalation.In some embodiments, the administration modality as described in U.S. Patent No. 5,543,158; No. 5,641,515 and No. 5,399,363 (each of which is specifically incorporated herein by reference in its entirety) may be used to deliver rAAV.In some embodiments, the preferred administration mode is by portal vein injection.
[0078] Pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions, and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain preservatives to prevent the growth of microorganisms. In many cases, the form is sterile and fluid to the extent that easy syringability is possible. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and / or vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Prevention of microbial action can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0079] For administration of an injectable aqueous solution, for example, the solution may be suitably buffered if necessary, and the liquid diluent is first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration. In this regard, the sterile aqueous media that can be used will be known to those skilled in the art. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and added to 1000 ml of subcutaneous infusion solution, or injected at the proposed infusion site (see, for example, Remington's Pharmaceutical Sciences 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the host. The person responsible for administration will, in any event, determine the dose appropriate for the individual host.
[0080] Sterile injectable solution is prepared by incorporating the required amount of active rAAV into a suitable solvent with various other components as listed herein as necessary, followed by sterilization by filtration.Generally, dispersion is prepared by incorporating various sterilized active components into a sterile vehicle that contains basic dispersion medium and other necessary components from those listed above.For the preparation of sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying technology, which produces powder of active components plus any additional desired components from the solution that has been previously sterilized and filtered.
[0081] The rAAV compositions disclosed herein may be formulated in a neutral or salt form. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the protein), which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acid, or organic acids such as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases such as isopropylamine, trimethylamine, histidine, procaine, and the like. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. The formulations are easily administered in a variety of dosage forms, such as injectable solutions, drug release capsules, and the like.
[0082] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, etc. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the composition. The phrase "pharmaceutical acceptable" refers to molecular entities and compositions that do not produce allergic or similar adverse reactions when administered to a host.
[0083] Delivery vehicles such as liposomes, nanocapsules, microparticles, microspheres, lipid particles, vesicles, etc. can be used to introduce the compositions of the present disclosure into suitable host cells. In particular, transgenes delivered by rAAV vectors can be formulated for delivery either encapsulated in lipid particles, liposomes, vesicles, nanospheres, nanoparticles, or the like.
[0084] Such formulations may be preferred for the introduction of pharma- ceutical acceptable formulations of nucleic acids or rAAV constructs disclosed herein. The formation and use of liposomes are generally known to those skilled in the art. Recently, liposomes with improved serum stability and circulation half-time have been developed (U.S. Patent No. 5,741,516). In addition, various methods of liposomes and liposome-like preparations as potential drug carriers have been described (U.S. Patent Nos. 5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587).
[0085] Liposomes have been used successfully in numerous cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been effectively used to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials have been completed examining the efficacy of liposome-mediated drug delivery.
[0086] Liposomes are formed from phospholipids dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles, also called multilamellar vesicles (MLVs). MLVs generally have diameters between 25 nm and 4 μm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200-500 A, which contain an aqueous solution in their core. Alternatively, nanocapsule formulations of rAAV may be used. Nanocapsules can generally capture substances in a stable and reproducible manner. To avoid side effects due to intracellular polymer overload, such ultrafine particles (size of about 0.1 μm) should be designed using polymers that can be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use.
[0087] In addition to the above delivery methods, the following techniques are also contemplated as alternative methods for delivering rAAV compositions to a host. Sonophoresis (i.e., ultrasound) is used as a device to enhance the rate and effectiveness of drug penetration into and through the circulatory system and is described in U.S. Patent No. 5,656,016. Other contemplated drug delivery alternatives are intraosseous injection (U.S. Patent No. 5,779,708), microchip devices (U.S. Patent No. 5,797,898), ophthalmic formulations (Bourlais et al., 1998), transdermal matrices (U.S. Patent Nos. 5,770,219 and 5,783,208) and feedback-controlled delivery (U.S. Patent No. 5,697,899).
[0088] Treatment method Aspects of the disclosure relate to compositions and methods for preventing or treating certain neurological and / or neuromuscular diseases, such as spinal muscular atrophy (SMA). The disclosure is based, in part, on isolated nucleic acids, rAAVs, etc., that include a codon-optimized nucleic acid sequence encoding the SMN1 protein. In some embodiments, the rAAV vector includes a native (e.g., human) SMN1 promoter, e.g., as set forth in SEQ ID NO: 4 or 5.
[0089] The present disclosure is based, in part, on increasing SMN1 protein expression using the rAAV and vectors described herein, which results in reduced toxicity in a subject (e.g., compared to a subject administered a previously used rAAV-SMN1 vector, e.g., Zolgensma). In some embodiments, the reduced toxicity is reduced liver toxicity. In some embodiments, the reduced toxicity is reduced dorsal root ganglion (DRG) toxicity. The amount of reduced toxicity in a subject can vary. In some embodiments, toxicity is reduced 2-5 fold, 3-10 fold, 5-20 fold, 10-50 fold, 30-80 fold, or 50-100 fold (e.g., compared to a subject administered a previously used rAAV-SMN1 vector). In some embodiments, toxicity is reduced by more than 100 fold (e.g., compared to a subject administered a previously used rAAV-SMN1 vector, e.g., Zolgensma). Methods for measuring toxicity in a subject are known, including measuring cytotoxicity (eg, cell death), liver toxicity (eg, by an ALT assay), and the like.
[0090] In some embodiments, administration results in a reduction in complications associated with SMA. In some embodiments, complications of SMA include pulmonary infections, spinal deformities (e.g., scoliosis, hip subluxation / dislocation), joint contractures, or respiratory failure. In some embodiments, administration results in improved survival in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1. In some embodiments, the survival rate of the subject is increased by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% compared to a subject administered a previously used rAAV-SMN1 vector (e.g., Zolgensma). Any suitable known method of measuring survival rate can be used in the present disclosure.
[0091] In some embodiments, the subject is a mammalian subject, e.g., a human subject. In some embodiments, the subject is characterized by having one or more mutations in the SMN1 or SMN2 gene, e.g., one or more mutations that result in a reduction (or absence) of functional SMN1 protein in the subject's cells. Examples of SMN1 mutations are described, e.g., by Wirth, Hum Mutat. 2000; 15(3): 228-37. In some embodiments, the subject has reduced (or no) functional SMN1 protein in its cells. In some embodiments, the subject is a non-human mammal, e.g., a mouse, rat, goat, sheep, pig, cow, camel, llama, or non-human primate.
[0092] In some embodiments, administration of an isolated nucleic acid, rAAV, or composition described herein to a cell or subject increases SMN1 expression in the cell or subject by 2-fold to 100-fold (e.g., 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 75-fold, 100-fold, etc.) compared to a control subject. As used herein, a "control" subject refers to a subject that has not been administered an isolated nucleic acid, rAAV, or composition described herein. In some embodiments, a control subject is the same subject that is administered an isolated nucleic acid, rAAV, or composition described herein (e.g., prior to administration).
[0093] In some aspects, the disclosure relates to a method for treating SMA in a subject, the method comprising administering to the subject an isolated nucleic acid, rAAV, or pharmaceutical composition described herein. As used herein, the term "preventing" refers to the application or administration of a composition comprising a transgene encoding an SMN1 protein to a subject who does not have a symptom or disease associated with aberrant SMN1 activity, but has a predisposition to a disease associated with aberrant SMN1 activity, for the purpose of stopping or delaying the onset of one or more symptoms of the disease associated with aberrant SMN1 activity. In some embodiments, the disease is SMA. In some embodiments, "preventing" also refers to stopping or delaying the onset of a complication associated with aberrant SMN1 activity as described herein, such as SMA.
[0094] As used herein, the term "treat" refers to the application or administration of a composition comprising a transgene encoding an SMN1 protein to a subject who does not have a symptom or disease associated with aberrant SMN1 activity, but has a predisposition to a disease associated with aberrant SMN1 activity, for the purpose of curing, curing, mitigating, alleviating, altering, treating, improving, ameliorating, or affecting a disorder, disease symptom, or predisposition to a disease associated with aberrant SMN1 activity. In some embodiments, the disease is SMA. In some embodiments, "treat" also refers to curing, curing, alleviating, alleviating, altering, treating, improving, ameliorating, or affecting a complication associated with aberrant SMN1 activity as described herein (e.g., SMA).
[0095] Alleviating a disease associated with abnormal SMN1 activity also includes delaying the onset or progression of the disease, or reducing the severity of the disease. Alleviating a disease does not necessarily require a curative effect. As used herein, "delaying" the onset of a disease (such as a disease associated with abnormal SMN1 activity, such as SMA) means delaying, preventing, slowing, retarding, stabilizing, and / or postponing the progression of the disease. This delay can be for a variety of lengths of time, depending on the history of the disease and / or the individual being treated. A method of "delaying" or alleviating the onset of a disease, or a method of delaying the onset of a disease, is a method that reduces the probability of developing one or more symptoms of the disease within a certain time frame and / or reduces the severity of the symptoms within a certain time frame, compared to not using the method. Such comparisons are based on clinical studies with a sufficient number of subjects to provide statistically significant results.
[0096] "Onset" or "progression" of a disease refers to early signs of disease and / or subsequent progression. Onset of a disease can be detected and assessed using standard clinical techniques as known in the art. However, onset also refers to progression that may be undetectable. For purposes of this disclosure, onset or progression refers to the biological course of a condition. "Onset" includes onset, recurrence, and onset. As used herein, "onset" or "onset" of a disease associated with aberrant SMN1 activity or angiogenesis includes initial onset and / or recurrence.
[0097] The compositions described herein can be administered (or transgenes expressed) to one or more target cells of a subject (e.g., a mammalian subject, such as a human). In some embodiments, the compositions (e.g., isolated nucleic acids, rAAVs, etc.) are administered to cells of the central nervous system (CNS) of the subject. Examples of CNS cells include, but are not limited to, neurons, astrocytes, glial cells, etc.
[0098] Kits and Related Compositions The agents described herein may in some embodiments be assembled into pharmaceutical kits or diagnostic kits or research kits to facilitate their use in therapeutic, diagnostic or research applications. The kits may include one or more containers that contain the components of the present disclosure and instructions. Specifically, such kits may include one or more agents together with instructions that describe the intended use and appropriate use of these agents. In some embodiments, the agents in the kits may be in pharmaceutical formulations and dosages suitable for a particular use and method of administration of the agents. Kits for research purposes may contain components in concentrations or amounts suitable for carrying out various experiments.
[0099] The kit may be designed to facilitate the use by researchers of the methods described herein and may take many forms. Each composition of the kit may be provided in liquid form (e.g., a solution) or in solid form (e.g., a dry powder), if applicable. In some cases, some of the compositions may be configurable (e.g., into an active form) or otherwise processable, for example, by the addition of a suitable solvent or other species (e.g., water or cell culture medium), which may or may not be provided in the kit. As used herein, "instructions" may define an instruction and / or promotion component, and may typically accompany written instructions on or associated with the packaging of the present disclosure. Instructions may also encompass any oral or electronic instructions, such as audiovisual (e.g., videotape, DVD, etc.), internet, and / or web-based communication, provided in any manner such that the user clearly recognizes that instructions should be associated with the kit. The written instructions may be in a form prescribed by a government agency regulating the manufacture, use, or sale of a drug or biological product, and the instructions may also reflect approval by the agency of the manufacture, use, or sale for animal administration.
[0100] The kit may contain any one or more of the components described herein in one or more containers. As an example, in one embodiment, the kit may include instructions for mixing one or more components of the kit and / or for isolating and mixing a sample and applying it to a subject. The kit may include a container that contains the agent described herein. The agent may be in liquid, gel or solid (powder) form. The agent may be sterilely prepared, packaged in a syringe, and shipped refrigerated. Alternatively, it may be housed in a vial or other container for storage. A second container may have another agent that is sterilely prepared. Alternatively, the kit may include an active agent that is premixed and shipped in a syringe, vial, tube, or other container. The kit may have one or more or all of the components necessary to administer the agent to an animal, such as a syringe, topical application device, or intravenous needle tube and bag, especially in the case of a kit for producing a particular somatic cell animal model.
[0101] The kit may have various forms, such as a blister pouch, shrink-wrap pouch, vacuum-sealable pouch, sealable thermoformed tray, or similar pouch or tray form, with accessories loosely packed in a pouch, one or more tubes, containers, boxes, or bags. The kit may be sterilized after the accessories are added, allowing the individual accessories in the container to be opened separately. The kit can be sterilized using any suitable sterilization technique, such as radiation sterilization, heat sterilization, or other sterilization methods known in the art. The kit may also include other components, such as containers, cell culture media, salts, buffers, reagents, syringes, needles, fabrics such as gauze for applying or removing disinfectants, disposable gloves, supports for medication before administration, etc., depending on the particular application.
[0102] The instructions included in the kit may include methods for constructing the AAV vectors described herein. In addition, the kits of the present disclosure may include instructions, negative and / or positive controls, containers, diluents and buffers for samples, sample preparation tubes, and printed or electronic reference AAV sequence listings for sequence comparison. EXAMPLES
[0103] Example 1 Intravenous administration of Zolgensma to individuals under the age of 2 years has shown significant clinical benefit in infants with type 1 SMA, although a rapid increase in liver transaminases was observed in most patients. Systemic administration of AAV9-like SMN vectors has been observed to induce toxicity, such as dorsal root ganglion (DRG) neurodegeneration and inflammation, in large animals. Chronic AAV9-mediated SMN overexpression in mouse models has been observed to induce dose-dependent delayed motor dysfunction. Thus, supraphysiological levels of SMN1 expression delivered by AAV may be a safety concern for AAV-based SMA gene therapy.
[0104] In this example, we describe modifying the AAV-SMN1 vector to address potential safety concerns. First, the SMN1 coding sequence (CDS) was codon-optimized to maximize SMN1 expression in order to reduce the vector dose delivered to patients. Second, the endogenous SMN1 promoter was used to drive AAV-based SMN1 expression in patients to increase the safety profile. Figure 1 shows a schematic diagram of the SMN1-encoding vector of the present disclosure. "scAAV-CB6-opt-SMN1" is a self-complementary AAV (scAAV) vector with a CB6 promoter and a codon-optimized SMN1 coding sequence. "SMNp-SMN1" is a single-stranded AAV genome with a 2.0 kb endogenous human SMN1 promoter and a codon-optimized SMN1 coding sequence (CDS). "ssAAV-opt-SMN1(MBL)" is a single-stranded AAV genome with 2.0 kb of the endogenous human SMN1 promoter, a synthetic MBL intron, and a codon-optimized SMN1 coding sequence (CDS). "SMNsp-SMN1" is a self-complementary AAV vector with 0.9 kb of the endogenous human SMN1 promoter and a codon-optimized SMN1 CDS. "Zolgensma" is a self-complementary AAV vector with the CMV enhancer / chicken beta actin promoter and wild-type human SMN1 CDS.
[0105] Expression of rAAV vectors encoding SMN1 was examined in vivo. Figures 2A-2F show representative data of ssAAV9.opt-SMN1 and Zolgensma in SMNΔ7 mice. Figure 2A shows survival curves of SMNΔ7 mice treated with Zolgensma (2xE14 genome copies (GC) / kg) or three doses of SMNp-SMN1 rAAV (2xE14 genome copies (GC) / kg, 6.8xE13 GCS / kg, or 3.4xE13 GCS / kg); treatment with the same or 1 / 3 dose of ssAAV9.opt-SMN1 shows higher survival rates than mice treated with Zolgensma. Figures 2B and 2C show representative data showing that ssAAV9.opt-SMN1-treated mice show similar weight gain compared to Zolgensma-treated mice. Figure 2D shows survival curves of scAAV9.opt-SMN1 and Zolgensma in SMNΔ7 mice; treatment with the same or 1 / 3 dose of ssAAV9.opt-SMN1 shows higher survival rates than mice treated with Zolgensma. Figures 2E and 2F show representative data showing that ssAAV9.opt-SMN1-treated mice show similar weight gain compared to Zolgensma-treated mice.
[0106] Figures 3A-3B show representative behavioral assay data from SMNΔ7 mice treated with scAAV9.opt-SMN1. Figure 3A shows that animals treated with scAAV9.opt-SMN1 are able to recover on their own from 5 days post-administration. Figure 3B shows representative data showing that all treated animals have functional muscles as measured by the rotarod test.
[0107] Figures 4A-4B show representative toxicological data. Figure 4A shows histological data indicating that high levels of SMN1 overexpression are toxic to liver cells. Briefly, AAV vectors were injected into animals at P0 via the facial vein at 5E+11 GC / mouse. Livers were harvested 8 days after injection. Liver damage was observed in the AAVsc-CB6-PI-SMN1 (6 / 6 animals) and Zolgensma (4 / 7 animals) vector treatment groups, but not in the control empty AAV9 (0 / 8 animals) or ssAAV9-opt-SMN1 (0 / 8) vector treatment groups. Figure 4B shows representative alanine aminotransferase (ALT) assay test results.
[0108] 5 shows a schematic diagram illustrating the recommended expression levels of vectors encoding SMN1. Briefly, the SMN1-encoding vectors described in this disclosure allow for high level expression of SMN1 in central nervous system (CNS) tissues without overexpression in muscle or non-target organs, which may cause liver toxicity in the subject.
[0109] The three improved SMN1-encoding rAAV vectors described in Figure 1 were packaged in AAV9 capsids. The rAAV was then injected into SMNΔ7 mice at P1, and the weight and survival of the mice were monitored. Both modified AAV-SMN1 vectors (e.g., SMNp-SMN1 and SMNsp-SMN1) outperform Zolgensma in survival. It was observed that a one-third dose (compared to Zolgensma) of the modified vector (e.g., 1.67xE11 genome copies (GC) per mouse) extends lifespan more efficiently than Zolgensma at 5xE11 GC per mouse (Figures 6A and 6C). Figure 6B shows that SMNΔ7 mice treated with SMNP-SMN1 at 5xE11 GC gained more weight from day 17 onwards than mice treated with Zolgensma, and the 1.67xE11 GC dose of SMNp-SMN1 caused mice to achieve similar weights at day 55 compared to the Zolgensma group. Mice treated with two different doses of SMNsp-SMN1 vector (5xE11 GC and 1.67xE11 GC) also showed a growth advantage from around day 23 compared to the 5xE11 GC dose of Zolgensma group (Figure 6D).
[0110] Example 2 To test whether an AAV vector carrying the codon-optimized sequence of hSMN1 (co-hSMN1) under the CMVen / CB promoter (CMVen / CB-co-hSMN1, SEQ ID NO: 8) induces liver toxicity, the AAV vector was packaged in an AAV9 capsid (rAAV9sc-CMVen / CB-co-hSMN1) and rAAV was administered to 1-day-old SMNdelta7 mice via facial vein injection at 3.3 x10e14 GCs / kg. All treated animals (n = 6) died earlier than untreated SMA mice. Animals treated with the vector showed yellowing of the skin and hepatocellular damage 8 days after injection (Figure 7A-7C). Overexpression of SMN1 was confirmed in the liver (Figure 7D).
[0111] Furthermore, we tested whether suppression of SMN expression in the liver would alleviate liver injury. To detarget rAAV from the liver, miR-122 binding sites were engineered into CMVen / CB-co-hSMN1 (CB6-Pi-opt hSMN1-miR-122 BS; SEQ ID NO: 9) and packaged into AAV9 capsids (scAAV9-CB6-PI-opt hSMN1-miR-122 BS) (Figure 8A). rAAV9sc-CMVen / CB-co-hSMN1 and scAAV9-CB6-PI-opt hSMN1-miR-122 BS were injected into 1-day-old SMNdelta7 mice, respectively. Hepatic expression of SMN1 and liver toxicity were evaluated. The results showed that by utilizing the miR-122 binding site in the AAV construct, SMN expression was suppressed from the liver ( Figure 8B ), and liver toxicity was not observed in mice treated with scAAV9-CB6-PI-opt hSMN1-miR-122 BS ( Figure 8C ).
[0112] Furthermore, physiological levels of hSMN1 expression could be restored with low effective doses of rAAV in appropriate cell types, potentially reducing liver toxicity. To achieve physiologically regulated expression of hSMN1, a second generation scAAV9 was designed to express co-hSMN1 from the endogenous short hSMN1 promoter (SEQ ID NO: 5) (SMN1sp-co-SMN1 (referred to as SMN1p-co-SMN1 in Figures 9D, 9E and 9J); SEQ ID NO: 7). scAAV9-CMVen / CB-opt-hSMN1 was used as a positive control. Neuro-2A cells were transfected with SMN1p-co-SMN1 or CMVen / CB-opt-hSMN1, and SMN1 expression was evaluated. The results show that the second generation constructs using the endogenous SMN promoter showed higher expression efficiency in Neuro-2A cells (Figure 9A).
[0113] SMN1p-co-hSMN1 (SEQ ID NO: 7) was then packaged in AAV9 capsids (scAAV9-SMNp-co-hSMN1) and injected into newborn SMA mice via facial vein injection (Figure 9B). Another group of SMA mice with scAAV9-CMVen / CB-hSMN1 carrying the same expression cassette used in Zolgensma® as the reference vector. AAVsc-SMNsp-co-hSMN1 vector or reference vector was injected into SMA mice via the facial vein at P0 to set up a side-by-side animal experiment. Mouse weight (Figure 9C) and survival rate (Figure 9D) were monitored daily. Mice treated with AAVsc-SMNsp-co-hSMN1 gained more weight than the reference vector group. Administration of AAVsc-SMNsp-co-hSMN1 vector significantly improved the life span of SMA mice. Animals treated with AAVsc-SMNsp-co-hSMN1 were healthy at 5 months of age (Figure 9E). Muscle function of mice was also evaluated. Treatment with AAVsc-SMNsp-co-hSMN1 resulted in better recovery of muscle function than the reference group. Grid test data show that SMA mice treated with AAVsc-SMNsp-co-hSMN1 were able to recover on their own faster than the reference mice (Figure 9F). The effect of treatment at P0 on the neuromuscular junction (NMJ) in young (P12) animals was also evaluated. Representative images of the transversus abdominis muscle (TVA) show the effect of treatment on recovery of innervation of the NMJ (Figure 9G). The structure of the neuromuscular junction in AAVsc-SMNsp-co-hSMN1-treated mice remained close to that of wild-type mice and recovered better than the reference-treated SMA mice (Figure 9H).
[0114] Furthermore, treatment with AAVsc-SMNsp-co-hSMN1 alleviated complications in SMA mice. Ear necrosis is one of the complications commonly seen in this animal model. The severity of this complication was classified into different disease levels (Figure 9I). Animals treated with AAVsc-SMNsp-co-hSMN1 were less severe than the reference animals (Figure 9J). Older animals were more severely affected. Data were collected from 90 days for AAVsc-SMNp-co-hSMN1-treated animals and 60 days for the reference-treated animals.
[0115] Administration of AAVsc-SMNsp-co-hSMN1 into SMA mice achieved an organ / tissue expression pattern similar to that of healthy carrier animals. Immunoblot assays showed that AAVsc-SMNsp-co-hSMN1 was preferentially expressed in the central nervous system, but not in peripheral tissues. The expression pattern of this vector is close to the natural distribution of SMN, similar to that of healthy control animals (Figure 9K-9L).
[0116] Additionally, survival of SMA mice administered AAVsc-SMNsp-co-hSMN1 or benchmark rAAV(BMK) was monitored at P5. Administration of the scAAV9-SMNsp-hSMN1 (7E+11 vg / mouse) vector resulted in a 50% survival rate in SMA mice up to 90 days post-injection, whereas none of the SMA mice administered the benchmark rAAV survived past 30 days post-injection (Figure 10).
[0117] Representative sequence Codon-optimized human SMN1 nucleic acid sequence (SEQ ID NO:1) ATGGCCATGAGCAGCGGCGGCAGTGGCGGCGGCGTGCCCGAGCAGGAGGATTCTGTGCTGTTCCGGAGAGGAACAGGCCAGAGCGATGACTCCGATATCTGGGACGACACAGCCCTTATCAAGGCCTACGACAAGGCCGTGGCCAGCTTTAAGCACGCCCTGAAGAATGGCGATATCTGCGAGACAAGCGGAAAGCCTAAGACCACCCCTAAAAGAAAGCCCGCCAAGAAAAACAAGTCCCAGAAAAAAAACACCGCCGCTAGCCTGCAGCAGTGGAAGGTGGGCGACAAATGCAGCGCCATCTGGTCCGAGGACGGCTGCATCTACCCTGCTACCATCGCCAGCATCGACTTCAAGCGGGAAACCTGCGTGGTGGTCTACACAGGCTATGGCAATAGGGAGGAACAAAATCTCTCTGATCTGCTGTCTCCTATTTGTGAAGTGGCTAACAACATCGAGCAGAACGCCCAGGAAAATGAGAACGAAAGCCAAGTGTCCACCGACGAGAGCGAGAACAGCAGAAGCCCTGGAAACAAGTCTGACAACATCAAGCCCAAGTCTGCCCCTTGGAACAGCTTCCTGCCCCCTCCTCCTCCAATGCCTGGCCCCAGACTGGGCCCCGGCAAGCCTGGCCTGAAGTTCAACGGCCCTCCTCCACCCCCTCCTCCTCCACCTCCCCATCTGCTGAGCTGCTGGCTGCCTCCTTTTCCCAGCGGCCCCCCTATCATCCCCCCACCACCTCCTATCTGTCCCGACAGCCTGGACGACGCCGATGCTCTGGGATCCATGCTGATCAGCTGGTACATGTCTGGCTACCACACCGGCTACTACATGGGCTTCCGGCAGAACCAGAAGGAAGGAAGATGCAGCCACAGCCTGAACTGA
[0118] >Wild-type SMN1 nucleic acid sequence (SEQ ID NO: 2) ATGGCGATGAGCAGCGGCGGCAGTGGTGGCGGCGTCCCGGAGCAGGAGGATTCCGTGCTGTTCCGGCGCGGCACAGGCCAGAGCGATGATTCTGACATTTGGGATGATACAGCACTGATAAAAGCATATGATAAAGCTGTGGCTTCATTTAAGCATGCTCTAAAGAATGGTGACATTTGTGAAACTTCGGGTAAACCAAAAACCACACCTAAAAAAAACC TGCTAAGAAGAATAAAAGCCAAAAAGAAGAATACTGCAGCTTCCTTACAACAGTGGAAAGTTGGGGGACAAATGTTCTGCCATTTGGTCAGAAGACGGTTGCATTTACCCAGCTACCATTGCTTCAATTGATTTTAAGAGAAACCTGTGTTGTGGTTTACACTGGATATGGAAATAGAGAGGAGCAAAATCTGTCCGATCTACTTTCCCCAATCTGTGAAG TAGCTAATAATATAGAACAGAATGCTCAAGAGAATGAAAATGAAAGCCAAGTTTCAACAGATGAAAGTGAGACTCCAGGTCTCCTGGAAATAATCAGATAACATCAAGCCCAAATCTGCTCCATGGAACTCTTTTCTCCCTCCACCACCCCCCATGCCAGGGCCAAGACTGGGACCAGGAAAGCCAGGTCTAAAATTCAATGGCCCACCACCGCCACCCG CCACCACCACCACCCCACTTACTATCATGCTGGCTGCCTCCATTTCCTTCTGGACCACCAATAATTCCCCCACCACCTCCCATATGTCCAGATTCTCTTGATGATGCTGATGCTTTGGGAAGTATGTTAATTCATGGTACATGAGTGGCTATCATACTGGCTATTATATGGGTTTTTAGACAAAATCAAAAGAAGGAAGGTGCTCACATTCCTTAAATTAA
[0119] >SMN1 amino acid sequence(sequence number 3) MAMSSGSGGGVPEQEDSVLFRRGTGQSDDSDIWDDTALIKAYDKAVASFKHALKNGDICETSGKPKTTPKRKPAKKNKSQKKNTAASLQQWKVGDKCSAIWSEDGCIYPATIASIDFKRETCVVVYTGYGNREEQNLSDLLSPICE VANNIEQNAQENENESQVSTDESENSRSPGNKSDNIKPKSAPWNSFLPPPPPMPGPRLGPGKPGLKFNGPPPPPPPPPPHLLSCWLPPFPSGPPIIPPPPPICPDSLDDADALGSMLISWYMSGYHTGYYMGFRQNQKEGRCSHSLN
[0120] >SMN1 long promoter nucleic acid sequence (SEQ ID NO:4)
[0121] >SMN1 short promoter nucleic acid sequence (SEQ ID NO:5) ggatgccagaggcgggcggaatntcttgagctcaggagttcgagaccagcctacacaatatgctccaaacgccgcttntacaaaacatacagaaactacccgggtgtggtggcgnncccctgtggtcctagatacttgggaggttgaggcgggaggatcgcttgagctcgggaggtcgaggctgcaatgagccgagatggtgccactgcattctgacgacagagcgagattccgtttcaaaacaaacaacaaataaggttgggggatcaaatatcttctagtgtttaaggatctgccttccttcctgcccccatgtttgtctttccttgtttgtctttatatagatcaagcaggttttaaattcctagtaggagcttacatttacttttccaagggggagggggaataaatatctacacacacacacacacacacacacacacacacacacacacacacacacacacaccacactggagttcgagacgaggcctaagcaacatgccgaaaccccgtctctactaaatacaaaaaatagctgagcttggtggcgcacgcctatagtcctagctactggggaggctgaggtgggaggatcgcttgagcccaagaagtcgaggctgcagtgagccgagatcgcgccgctgcactccagcctgagcgacagggcgaggctctgtctcaaaacaaacaaacaaaaaaaaaaaggaaaggaaatataacacagtgaaatgaaaggattgagagaaatgaaaaatatacacgccacaaatgtgggagggcgataaccactcgtagaaagcgtgagaagttactacaagcggtcctcccgggcaccgtactgttccgctcccagaagccccgggcgccggaagtcgtcactcttaagaagggacggggccccacgctgcgcacccgcgggtttgc
[0122] >SMNlp - co - SMN1 rAAV vector nucleic acid sequence (SEQ ID NO: 6)
[0123] >SMN1sp-co-SMN1 rAAV vector nucleic acid sequence (SEQ ID NO:7)
[0124] >CMVen / CB-co-hSMN1 rAAV vector nucleic acid sequence (SEQ ID NO:8)
[0125] >CMVen / CB-co-hSMN1_miR122_BS rAAV vector nucleic acid sequence (SEQ ID NO:9)
[0126] >SMNlp-co-SMN1_miR122_BS rAAV vector nucleic acid sequence (SEQ ID NO: 10)
[0127] > SMNsp-co-SMN1_miR122_BS rAAV vector nucleic acid sequence (SEQ ID NO: 11)
Claims
1. A recombinant adeno-associated virus (rAAV) vector comprising a transgene comprising the endogenous SMN1 promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).
2. The rAAV vector of claim 1, wherein the codon-optimized nucleic acid sequence comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:
1.
3. The rAAV vector of claim 1 or 2, wherein the codon-optimized nucleic acid sequence comprises or consists of the sequence represented by SEQ ID NO:
1.
4. The rAAV vector of any one of claims 1 to 3, wherein the codon-optimized nucleic acid sequence does not include the nucleic acid sequence represented by SEQ ID NO:
2.
5. The rAAV vector of any one of claims 1 to 3, wherein human SMN1 comprises the amino acid sequence represented by SEQ ID NO:
3.
6. The rAAV vector of any one of claims 1 to 5, wherein the endogenous SMN1 promoter is a human SMN1 promoter.
7. The rAAV vector of any one of claims 1 to 6, wherein the endogenous SMN1 promoter comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO: 4 or 5.
8. 8. The rAAV vector of any one of claims 1 to 7, wherein the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:
4.
9. 8. The rAAV vector of any one of claims 1 to 7, wherein the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:
5.
10. The rAAV vector of any one of claims 1 to 9, further comprising one or more miR-122 binding sites.
11. The rAAV vector of claim 10, wherein the one or more miR-122 binding sites are located between the codon-optimized nucleic acid sequence encoding human SMN1 and the 3' ITR.
12. The rAAV vector of any one of claims 1 to 11, wherein at least one of the AAV ITRs is an AAV2 ITR.
13. The rAAV vector of any one of claims 1 to 12, wherein at least one of the AAV ITRs is a mutated ITR (mTR).
14. A vector comprising an rAAV vector described in any one of claims 1 to 13.
15. The vector of claim 14, wherein the vector is a plasmid or a baculovirus vector.
16. A cell comprising an rAAV vector according to any one of claims 1 to 13, or a vector according to claim 14 or 15.
17. An isolated nucleic acid comprising a nucleic acid sequence represented by SEQ ID NO:1 or any one of SEQ ID NOs:6-11.
18. 18. The isolated nucleic acid of claim 17, further comprising an endogenous SMN1 promoter operably linked to the nucleic acid sequence.
19. 19. The isolated nucleic acid of claim 18, wherein the endogenous SMN1 promoter is a human SMN1 promoter, optionally wherein the SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO: 4 or 5.
20. Recombinant adeno-associated viruses (rAAV), including: (i) a recombinant adeno-associated virus (rAAV) vector comprising a transgene, the transgene comprising the endogenous SMN1 promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs); and (ii) at least one AAV capsid protein;
21. The rAAV of claim 20, wherein the codon-optimized nucleic acid sequence comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:
1.
22. The rAAV of claim 20 or 21, wherein the codon-optimized nucleic acid sequence comprises or consists of the sequence represented by SEQ ID NO:
1.
23. The rAAV of any one of claims 20 to 22, wherein the codon-optimized nucleic acid sequence does not include the nucleic acid sequence represented by SEQ ID NO:
2.
24. The rAAV of any one of claims 20 to 23, wherein human SMN1 comprises the amino acid sequence represented by SEQ ID NO:
3.
25. The rAAV of any one of claims 20 to 24, wherein the endogenous SMN1 promoter is a human SMN1 promoter.
26. The rAAV of any one of claims 20 to 25, wherein the endogenous SMN1 promoter comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO: 4 or 5.
27. The rAAV of any one of claims 20 to 26, wherein the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:
4.
28. The rAAV of any one of claims 20 to 26, wherein the endogenous SMN1 promoter comprises or consists of the nucleic acid sequence represented by SEQ ID NO:
5.
29. The rAAV of any one of claims 20 to 28, further comprising one or more miR-122 binding sites.
30. The rAAV of claim 29, wherein the one or more miR-122 binding sites are located between the codon-optimized nucleic acid sequence encoding human SMN1 and the 3' ITR.
31. The rAAV of any one of claims 20 to 30, wherein at least one of the AAV ITRs is an AAV2 ITR.
32. The rAAV of any one of claims 20 to 31, wherein at least one of the AAV ITRs is a mutated ITR (mTR).
33. The rAAV of any one of claims 20 to 32, wherein the rAAV is a self-complementary AAV (scAAV).
34. The rAAV of any one of claims 20 to 33, wherein at least one AAV capsid protein is an AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9 capsid protein, or a variant thereof.
35. The rAAV of any one of claims 20 to 34, wherein at least one AAV capsid protein is an AAV9 capsid protein.
36. A pharmaceutical composition comprising an rAAV vector or rAAV described in any one of claims 1 to 35, and a pharma- ceutically acceptable excipient.
37. A method for delivering an introduced gene to a cell, the method comprising administering to the cell an rAAV vector described in any one of claims 1 to 13, an rAAV described in any one of claims 20 to 35, or a pharmaceutical composition described in claim 36.
38. 38. The method of claim 37, wherein the cell is a mammalian cell.
39. 39. The method of claim 37 or 38, wherein the cell is a human cell.
40. The method of any one of claims 37 to 39, wherein the cell is in a subject.
41. 41. The method of claim 40, wherein the subject has or is suspected of having spinal muscular atrophy (SMA).
42. A method for preventing or treating spinal muscular atrophy (SMA) in a subject, comprising administering to the subject an rAAV vector described in any one of claims 1 to 13, an rAAV described in any one of claims 20 to 35, or a pharmaceutical composition described in claim 36.
43. 43. The method of claim 42, wherein the subject is a mammal.
44. 44. The method of claim 42 or 43, wherein the subject is a human.
45. 45. The method of any one of claims 42 to 44, wherein the subject has one or more mutations in the SMN1 gene.
46. 46. The method of any one of claims 42-45, wherein administering comprises systemic or local injection.
47. 47. The method of claim 46, wherein the systemic injection comprises intravenous injection.
48. 48. The method of any one of claims 42-47, wherein administering comprises injection into the central nervous system (CNS) of the subject.
49. The method of any one of claims 42-48, wherein administration results in a reduced amount of dorsal root ganglion (DRG) toxicity in the subject compared to administration to the subject of an rAAV comprising a constitutive promoter operably linked to a wild-type SMN1 coding sequence.
50. 50. The method of any one of claims 42-49, wherein administration results in reduced liver toxicity in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1.
51. 51. The method of any one of claims 42-50, wherein administration results in a reduction of complications associated with SMA.
52. 52. The method of any one of claims 42-51, wherein administration results in improved survival in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1.
53. 52. The method of claim 51, wherein complications of SMA include pulmonary infection, spinal deformity (e.g., scoliosis, hip subluxation / dislocation), joint contracture, or respiratory failure.
54. A recombinant adeno-associated virus (rAAV) vector comprising a transgene comprising a promoter operably linked to a codon-optimized nucleic acid sequence encoding human SMN1 and flanked by adeno-associated virus (AAV) inverted terminal repeats (ITRs).
55. The rAAV vector of claim 54, wherein the codon-optimized nucleic acid sequence comprises a nucleic acid sequence that is at least 70%, 80%, 90%, 95%, or 99% identical to the nucleic acid sequence represented by SEQ ID NO:
1.
56. 56. The rAAV vector of claim 54 or 55, wherein the codon-optimized nucleic acid sequence comprises or consists of the sequence represented by SEQ ID NO:
1.
57. The rAAV vector of any one of claims 54 to 56, wherein the codon-optimized nucleic acid sequence does not include the nucleic acid sequence represented by SEQ ID NO:
2.
58. 58. The rAAV vector of any one of claims 54 to 57, wherein human SMN1 comprises the amino acid sequence represented by SEQ ID NO:
3.
59. The rAAV vector of any one of claims 54 to 58, wherein the promoter is a CB6 promoter.
60. The rAAV vector of any one of claims 54 to 59, wherein the rAAV vector further comprises a CMV enhancer.
61. The rAAV vector of any one of claims 54 to 60, further comprising one or more miR-122 binding sites.
62. The rAAV vector of claim 61, wherein the one or more miR-122 binding sites are located between the codon-optimized nucleic acid sequence encoding human SMN1 and the 3' ITR.
63. The rAAV vector of any one of claims 54 to 62, wherein at least one of the AAV ITRs is an AAV2 ITR.
64. The rAAV vector of any one of claims 54 to 63, wherein at least one of the AAV ITRs is a mutated ITR (mTR).
65. A vector comprising the rAAV vector of any one of claims 54 to 64.
66. 66. The vector of claim 65, wherein the vector is a plasmid or a baculovirus vector.
67. A cell comprising an rAAV vector according to any one of claims 54 to 64, or a vector according to claim 65 or 66.
68. Recombinant adeno-associated viruses (rAAV), including: (a) (i) 5' ITR; (ii) a human short SMN promoter comprising the nucleotide sequence of SEQ ID NO:5; (iii) a codon-optimized nucleic acid sequence encoding SMN1 as set forth in SEQ ID NO:1; (iv) a polyA tail; and (v) 3' ITR A self-complementary rAAV genome comprising: (b) AAV9 capsid protein.
69. The rAAV of claim 68, wherein the polyA tail is a rabbit globin polyA or a BGH polyA tail.
70. The rAAV of claim 68 or 69, further comprising one or more miR-122 binding sites.
71. Recombinant adeno-associated viruses (rAAV), including: (i) a recombinant adeno-associated virus (rAAV) vector according to any one of claims 54 to 65, and (ii) at least one AAV capsid protein;
72. The rAAV of claim 71, wherein the rAAV is a self-complementary AAV (scAAV).
73. The rAAV of claim 71 or 72, wherein at least one AAV capsid protein is an AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, or AAV9 capsid protein, or a variant thereof.
74. 74. The rAAV of any one of claims 71 to 73, wherein at least one AAV capsid protein is an AAV9 capsid protein.
75. A method for preventing or treating spinal muscular atrophy (SMA) in a subject, comprising administering to the subject an rAAV vector described in any one of claims 54 to 64, or an rAAV described in any one of claims 71 to 74.
76. 76. The method of claim 75, wherein the subject is a mammal.
77. 77. The method of claim 75 or 76, wherein the subject is a human.
78. 78. The method of any one of claims 75 to 77, wherein the subject has one or more mutations in the SMN1 gene.
79. 79. The method of any one of claims 75-78, wherein administering comprises systemic or local injection.
80. 80. The method of claim 79, wherein the systemic injection comprises intravenous injection.
81. 81. The method of any one of claims 75-80, wherein administering comprises injection into the central nervous system (CNS) of the subject.
82. The method of any one of claims 75-81, wherein administration results in a reduced amount of dorsal root ganglion (DRG) toxicity in the subject compared to administration to the subject of a rAAV comprising a constitutive promoter operably linked to a wild-type SMN1 coding sequence.
83. The method of any one of claims 75-82, wherein administration results in reduced liver toxicity in the subject compared to administration of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1.
84. 84. The method of any one of claims 75-83, wherein administration results in a reduction of complications associated with SMA.
85. The method of any one of claims 74-83, wherein administration results in improved survival in the subject compared to administration to the subject of an AAV vector comprising a constitutive promoter operably linked to a nucleic acid encoding human SMN1.
86. 85. The method of claim 84, wherein complications of SMA include pulmonary infection, spinal deformity (e.g., scoliosis, hip subluxation / dislocation), joint contracture, or respiratory insufficiency.
